Aimmune's IPO nets $149mm
Executive Summary
Aimmune Therapeutics Inc. (food allergy desensitization therapies) netted $149mm through its initial public offering of 10mm shares at $16. (The company had hoped to sell 8.3mm shares between $14-16.) Existing investors agreed to purchase 1.56mm of the IPO shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice